Joint & CartilageCARTALAX
20MG
$70
Description
Cartalax is a bioregulatory tripeptide (Ala-Glu-Asp) developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. It belongs to the Khavinson class of short peptide bioregulators designed to target specific tissues through epigenetic mechanisms. Cartalax specifically targets cartilage and musculoskeletal tissue, promoting chondrocyte function, cartilage matrix synthesis, and joint tissue maintenance. It works at the gene expression level to normalize protein synthesis in cartilage cells, supporting the structural integrity and regenerative capacity of joint tissue. Cartalax is particularly relevant to aging research, as cartilage degradation is a hallmark of musculoskeletal aging.
Potential Benefits
Research Notes
Cartalax was developed as part of the Khavinson peptide bioregulation program, which has produced multiple organ-specific short peptides validated through decades of research. Published studies in the Bulletin of Experimental Biology and Medicine and Advances in Gerontology demonstrate that short bioregulatory peptides like Cartalax can interact with DNA to modulate tissue-specific gene expression. Research shows improvements in cartilage tissue markers and musculoskeletal function in aging models.
Usage Information
For research and educational purposes only. Consult with a qualified professional before use.
All peptides must be refrigerated upon receipt.
RESEARCH PURPOSES ONLY
This product is intended for research and educational purposes only. Not intended for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.